OTC · Medical - Distribution

Sinopharm Group Co. Ltd. (SHTDF) Stock

$2.13 +0.00% OTC: SHTDF Healthcare

Sinopharm Group Co. Ltd., along with its affiliates, plays a significant role in the People's Republic of China's healthcare sector, primarily engaging in the wholesale and retail trade of pharmaceuticals, medical equipment, and health-related products.

Valuation

MetricValue
Price$2.13
Market Cap$6.65B
P/E Ratio6.40
P/B Ratio0.55
P/S Ratio0.08
EPS (TTM)$0.33
52-Week High$2.70
52-Week Low$2.13
Dividend Yield4.69%

Financials & Margins

MetricValue
ROE8.70%
ROA1.83%
ROCE10.95%
Gross Margin7.32%
Operating Margin2.74%
Net Margin1.24%
Debt/Equity1.29
Current Ratio1.41

Annual Financials (USD)

Metric20212022202320242025
Revenue$521.1B$552.1B$596.6B$584.5B$560.3B
Operating Profit$19.7B$20.6B$20.2B$16.2B$16.2B
Net Profit$7.8B$8.5B$9.1B$7.0B$7.0B
EPS$2.49$2.73$2.90$2.26$2.24
Op Margin3.8%3.7%3.4%2.8%2.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$335.4B$364.8B$383.4B$392.8B$390.6B
Total Liabilities$235.8B$254.7B$263.1B$266.1B$256.3B
Cash$43.5B$55.2B$63.8B$54.3B$61.6B
Borrowings$68.4B$69.6B$73.8B$76.4B$108.6B

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$9.3B$21.0B$17.2B$11.5B$14.1B
Investing Cash Flow$-3.5B$-6.0B$-3.3B$-5.8B$-2.6B
Financing Cash Flow$-7.8B$-8.1B$-7.6B$-4.6B$-5.7B
Net Cash Flow$-6.6B$11.7B$8.6B$-9.5B$-5.5B
Free Cash Flow$7.1B$18.5B$14.8B$9.6B$12.5B

Valuation & Return Ratios

MetricValue
PEG Ratio4.82
EV / EBITDA4.56
FCF Yield22.95%
Quick Ratio1.15
Interest Coverage9.36
Return 1Y-11.25%
Return 3Y-24.80%
Return 5Y-11.18%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CNVVFConvaTec Group Plc $2.95 +4.61% 32.81 $5.75B 3.73%
CNVVYConvaTec Group Plc $11.70 +0.97% 32.81 $5.72B 3.68%
GNGBYGetinge AB (publ) $23.97 +0.23% 23.72 $6.53B 2.13%
GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited $2.34 +0.00% 12.06 $6.20B 5.56%
MSMKFMatsukiyoCocokara & Co. $14.88 +0.00% 17.37 $5.85B 2.28%

About Sinopharm Group Co. Ltd.

Sinopharm Group Co. Ltd., along with its affiliates, plays a significant role in the People's Republic of China's healthcare sector, primarily engaging in the wholesale and retail trade of pharmaceuticals, medical equipment, and health-related products. The company organizes its extensive operations across four distinct divisions. Its Pharmaceutical Distribution unit supplies a wide array of medicinal products to various clients, including hospitals, other distributors, retail pharmacies, and clinics. This segment also provides comprehensive distribution, logistics, and additional value-added services for both domestic and international pharmaceutical and healthcare product manufacturers and suppliers. The Medical Devices segment is dedicated to the distribution of medical equipment. Through its Retail Pharmacy division, the company oversees and franchises a substantial network of drugstores, which totaled 10,259 locations as of December 31, 2021. The Other Business segment is involved in the manufacturing and sale of pharmaceuticals, chemical reagents, and laboratory supplies. Beyond these core areas, the company's activities extend to property leasing and management; the trade of specialized medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products; information technology development; a variety of consulting services (medicine, health, business, market information); investment management; import and export; and convention and exhibition services. Additionally, it manages medical project investments, consulting, and technology training initiatives. Sinopharm Group Co. Ltd. has formed a strategic partnership with I-Mab to enhance its commercial reach and market transformation efforts. The company was established in 2003, with its headquarters located in Shanghai, China, and operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Sinopharm Group Co. Ltd. is headquartered in CN.

Sinopharm Group Co. Ltd. (SHTDF) stock trades at $2.13 with a market capitalization of $6.65B. The stock is valued at a price-to-earnings (P/E) ratio of 6.40, price-to-book of 0.55, price-to-sales of 0.08. Over the past 52 weeks the stock has ranged between $2.13 and $2.70, and currently trades 21.1% below its 52-week high. It pays a dividend yielding 4.69%.

On profitability, Sinopharm Group Co. Ltd. generates a return on equity (ROE) of 8.70%, return on capital employed of 10.95%, an operating margin of 2.74%, a net profit margin of 1.24%.

Official website: www.sinopharmgroup.com.cn

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides